GSK will publish details of 13,500 chemical compounds from its own library that have potential to act against the parasite that causes malaria in sub-Saharan Africa, killing at least one million children every year. It took a team of five investigators a year to screen the two million compounds in GSK's library - its entire collection of potential drugs and possibly the biggest such library in the world.Here a company is surrendering its intellectual property for the greater good. While this might be admirable on a moral level, I'm not so sure shareholders should be pleased. This isn't a situation where Glaxo has some profits, and feels like donating a portion to a cause. This isn't even a situation where it developed a revolutionary new drug and wants to give it away for free to those who need it. Instead, the company invested countless millions of dollars in drug research to come up with those 13,500 chemical compounds. That investment, of course, came from shareholders. So in a more direct way, Glaxo management has decided to take investor dollars and donate the profit that may come from it to the world -- without knowing what that profit may be. Because remember, this is raw intellectual property -- not an end product. Maybe one of those compounds also holds a cure for some other disease completely unrelated to malaria, unbeknownst to Glaxo. But now that drug would be in the public domain, much to the dismay of shareholders who thought their dollars would be directed at investment to reap profit. Again, don't get me wrong: on many levels a donation like this seems wonderful for the world. And if shareholders go along with it, then by all means, Glaxo should donate away. But without explicit shareholder approval, I'm a little unclear how this is different from taking investors' money and misappropriating it. In this case, that end happens to something most people consider ethically courageous -- hoping to cure an awful disease in poor countries. But if that money was appropriated in a less ethical manner without shareholder consent -- say, a trip of leisure for the CEO and his wife to Barbados -- how would that be any different from a logistical standpoint?
This article available online at: